Aurinia Pharmaceuticals Inc. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
Aurinia Pharmaceuticals Inc. (AUPH) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of $500.00 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2024-11-07
- Aurinia Pharmaceuticals Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2024-09-30 was $500.00K, a 400.00% increase year-over-year.
- Aurinia Pharmaceuticals Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2024-06-30 was -$5.00K.
- Aurinia Pharmaceuticals Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2024-03-31 was -$124.00K, a 269.86% decline year-over-year.
- Aurinia Pharmaceuticals Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2023-12-31 was $231.00K, a 52.95% decline year-over-year.
- Aurinia Pharmaceuticals Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2023 was $331.00K.
- Aurinia Pharmaceuticals Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2022 was -$209.00K.
- Aurinia Pharmaceuticals Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2021 was -$47.00K.
- Aurinia Pharmaceuticals Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2020 was -$47.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month as first filed | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month as first filed | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2024-09-30 | $500.00K 10-Q · filed 2024-11-07 | $495.00K derived: sum of 2 quarters · filed 2024-11-07 | $300.00K 10-Q · filed 2024-11-07 | $602.00K derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2024-06-30 | -$5.00K 10-Q · filed 2024-08-01 | -$129.00K 10-Q · filed 2024-08-01 | $102.00K derived: sum of 3 quarters · filed 2024-08-01 | $202.00K derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2024-03-31 | -$124.00K 10-Q · filed 2024-05-02 | $107.00K derived: sum of 2 quarters · filed 2024-05-02 | $207.00K derived: sum of 3 quarters · filed 2024-11-07 | $175.00K derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2023-12-31 | $231.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $331.00K derived: sum of 2 quarters · filed 2024-11-07 | $299.00K derived: sum of 3 quarters · filed 2024-11-07 | $331.00K 10-K · filed 2024-02-15 | |||
| 2023-09-30 | $100.00K 10-Q · filed 2024-11-07 | $73.00K 10-Q · filed 2023-11-02 | $68.00K derived: sum of 2 quarters · filed 2024-11-07 | $100.00K 10-Q · filed 2024-11-07 | $114.00K 10-Q · filed 2023-11-02 | $632.00K derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$32.00K 10-Q · filed 2024-08-01 | $41.00K 10-Q · filed 2024-08-01 | $532.00K derived: sum of 3 quarters · filed 2024-08-01 | $832.00K derived: sum of 4 quarters · filed 2024-08-01 | |||
| 2023-03-31 | $73.00K 10-Q · filed 2024-05-02 | $100.00K 10-Q · filed 2023-05-04 | $564.00K derived: sum of 2 quarters · filed 2024-05-02 | $864.00K derived: sum of 3 quarters · filed 2024-05-02 | $1.10M derived: sum of 4 quarters · filed 2024-05-02 | ||
| 2022-12-31 | $491.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $791.00K derived: sum of 2 quarters · filed 2024-02-15 | $1.03M derived: sum of 3 quarters · filed 2024-02-15 | -$209.00K 10-K · filed 2024-02-15 | -$300.00K 10-K · filed 2023-02-28 | ||
| 2022-09-30 | $300.00K 10-Q · filed 2023-11-02 | $535.00K derived: sum of 2 quarters · filed 2023-11-02 | -$700.00K 10-Q · filed 2023-11-02 | $1.25M derived: sum of 4 quarters · filed 2023-11-02 | |||
| 2022-06-30 | $235.00K 10-Q · filed 2022-08-04 | $1.00M 10-Q · filed 2022-08-04 | $954.00K derived: sum of 3 quarters · filed 2022-08-04 | $952.00K derived: sum of 4 quarters · filed 2022-08-04 | |||
| 2022-03-31 | $766.00K 10-Q · filed 2022-05-10 | $719.00K derived: sum of 2 quarters · filed 2022-05-10 | $717.00K derived: sum of 3 quarters · filed 2022-05-10 | $724.00K derived: sum of 4 quarters · filed 2022-05-10 | |||
| 2021-12-31 | -$47.00K 10-K · filed 2022-02-28 | -$49.00K derived: sum of 2 quarters · filed 2022-02-28 | -$42.00K derived: sum of 3 quarters · filed 2022-02-28 | -$47.00K 10-K · filed 2024-02-15 | |||
| 2021-09-30 | -$2.00K 10-Q · filed 2021-11-03 | $5.00K derived: sum of 2 quarters · filed 2021-11-03 | $11.00K 10-Q · filed 2021-11-03 | ||||
| 2021-06-30 | $7.00K 10-Q · filed 2021-08-05 | $13.00K 10-Q · filed 2021-08-05 | |||||
| 2021-03-31 | $6.00K 10-Q · filed 2022-05-10 | ||||||
| 2020-12-31 | -$47.00K 10-K · filed 2023-02-28 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |